论文部分内容阅读
目的评价丹红注射液联合静脉溶栓治疗急性心肌梗死的复合临床事件发生率及安全性。方法采用随机对照收集我院符合条件的急性心肌梗死静脉溶栓患者共48例,随机分为丹红组与对照组:对照组按常规溶栓方案治疗;丹红组在常规溶液栓治疗基础上加用丹红注射液20m l加入生理盐水250m l静脉滴注,每天一次,疗程2周,以用药2周内的复合临床事件发生率作为主要试验终点,同时观察出血.过敏等情况。结果48例入选对象中丹红26例与对照组22例2周内复合临床事件的发生率对比,丹红组低于对照组(19.2%vs 45.5%,P=0.049)。而出血发生率两组无显著性差异,两组均未见重度出血或致命性颅内出血。结论丹红注射液联合静脉溶栓治疗急性心肌梗塞可以降低复合临床事件的发生率,故临床应用安全有效。
Objective To evaluate the incidence and safety of compound clinical events of Danhong injection combined with intravenous thrombolysis in the treatment of acute myocardial infarction. Methods A randomized controlled trial of 48 patients with acute myocardial infarction venous thrombolysis in our hospital were randomly divided into Danhong group and control group: the control group was treated by conventional thrombolytic therapy; Danhong group was treated with conventional solution-based suppositories Add Danhong injection 20m l by adding saline 250ml intravenous drip once a day for 2 weeks to take the drug within 2 weeks of composite clinical events as the main endpoint, while bleeding, allergy and so on. Results The incidence of composite clinical events in 26 cases of Danhong in 48 cases and 22 cases in control group within 2 weeks was lower than that in control group (19.2% vs 45.5%, P = 0.049). The incidence of bleeding was no significant difference between the two groups, no severe bleeding or fatal intracranial hemorrhage in both groups. Conclusion Danhong injection combined with intravenous thrombolysis in the treatment of acute myocardial infarction can reduce the incidence of composite clinical events, so the clinical application of safe and effective.